LIN vs RMD · P/E 34, rev $33.99B vs P/E 29, $37.68B cap
Linde plc Ordinary Shares (LIN) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
RMD does not have a complete income-statement cache yet.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the LIN and RMD stock pages for the full models.
Not investment advice.